335 related articles for article (PubMed ID: 32255671)
1. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
2. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
5. Targeted thorium-227 conjugates as treatment options in oncology.
Karlsson J; Schatz CA; Wengner AM; Hammer S; Scholz A; Cuthbertson A; Wagner V; Hennekes H; Jardine V; Hagemann UB
Front Med (Lausanne); 2022; 9():1071086. PubMed ID: 36726355
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
7. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177
[TBL] [Abstract][Full Text] [Related]
8. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
[TBL] [Abstract][Full Text] [Related]
9. Thorium chelators for targeted alpha therapy: Rapid chelation of thorium-226.
Ferrier MG; Li Y; Chyan MK; Wong R; Li L; Spreckelmeyer S; Hamlin DK; Mastren T; Fassbender ME; Orvig C; Wilbur DS
J Labelled Comp Radiopharm; 2020 Oct; 63(12):502-516. PubMed ID: 32812275
[TBL] [Abstract][Full Text] [Related]
10. An efficient chelator for complexation of thorium-227.
Ramdahl T; Bonge-Hansen HT; Ryan OB; Larsen S; Herstad G; Sandberg M; Bjerke RM; Grant D; Brevik EM; Cuthbertson AS
Bioorg Med Chem Lett; 2016 Sep; 26(17):4318-21. PubMed ID: 27476138
[TBL] [Abstract][Full Text] [Related]
11. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.
Zhou X; Dong L; Shen L
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834087
[TBL] [Abstract][Full Text] [Related]
12. Advances in targeted alpha therapy for prostate cancer.
De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
15. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Sep; 43(9):1440-1449. PubMed ID: 28402142
[TBL] [Abstract][Full Text] [Related]
16. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Wickstroem K; Karlsson J; Ellingsen C; Cruciani V; Kristian A; Hagemann UB; Bjerke RM; Ryan OB; Linden L; Mumberg D; Brands M; Cuthbertson A
Pharmaceuticals (Basel); 2019 Oct; 12(4):. PubMed ID: 31618864
[TBL] [Abstract][Full Text] [Related]
19. Development of Targeted Alpha Particle Therapy for Solid Tumors.
Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
[TBL] [Abstract][Full Text] [Related]
20. Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy.
Deblonde GJ; Lohrey TD; Booth CH; Carter KP; Parker BF; Larsen Å; Smeets R; Ryan OB; Cuthbertson AS; Abergel RJ
Inorg Chem; 2018 Nov; 57(22):14337-14346. PubMed ID: 30372069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
